Caribou Biosciences, Inc. Financing Cash Flow
Caribou Biosciences, Inc. (CRBU) reported Financing Cash Flow of $20.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $17.94M, a 298833.33% increase year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.70M, a 476.07% increase year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.07M, a 5.36% increase year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $277.00K, a 13.52% increase year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $4.82M, a 71.17% decline from fiscal 2024.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $16.72M, a 89.16% decline from fiscal 2023.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $154.30M, a 7133.85% increase from fiscal 2022.
- Caribou Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $2.13M, a 99.51% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $20.63M 10-Q · filed 2026-08-13 | $24.70M derived: sum of 3 quarters · filed 2026-08-13 | $24.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-07 | $6.77M derived: sum of 2 quarters · filed 2026-05-07 | $7.04M derived: sum of 3 quarters · filed 2026-05-07 | $7.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.35M derived: sum of 2 quarters · filed 2026-03-05 | $4.35M derived: sum of 3 quarters · filed 2026-08-13 | $4.82M 10-K · filed 2026-03-05 |
| 2025-09-30 | $277.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $283.00K derived: sum of 2 quarters · filed 2026-08-13 | $751.00K 10-Q · filed 2025-11-12 | $4.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $474.00K 10-Q · filed 2026-08-13 | $4.34M derived: sum of 3 quarters · filed 2026-08-13 | $4.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $468.00K 10-Q · filed 2026-05-07 | $4.33M derived: sum of 2 quarters · filed 2026-05-07 | $4.58M derived: sum of 3 quarters · filed 2026-05-07 | $4.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.11M derived: sum of 2 quarters · filed 2026-03-05 | $4.24M derived: sum of 3 quarters · filed 2026-03-05 | $16.72M 10-K · filed 2026-03-05 |
| 2024-09-30 | $244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $376.00K derived: sum of 2 quarters · filed 2025-11-12 | $12.86M 10-Q · filed 2025-11-12 | $12.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $12.62M 10-Q · filed 2025-08-12 | $12.57M derived: sum of 3 quarters · filed 2025-08-12 | $147.70M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $12.48M 10-Q · filed 2025-05-08 | $12.44M derived: sum of 2 quarters · filed 2025-05-08 | $147.57M derived: sum of 3 quarters · filed 2025-05-08 | $165.14M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $135.09M derived: sum of 2 quarters · filed 2025-03-10 | $152.66M derived: sum of 3 quarters · filed 2025-03-10 | $154.30M 10-K · filed 2025-03-10 |
| 2023-09-30 | $135.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $152.70M derived: sum of 2 quarters · filed 2024-11-06 | $154.34M 10-Q · filed 2024-11-06 | $154.47M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $17.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $19.21M 10-Q · filed 2024-08-06 | $19.34M derived: sum of 3 quarters · filed 2024-08-06 | $19.99M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-07 | $1.77M derived: sum of 2 quarters · filed 2024-05-07 | $2.42M derived: sum of 3 quarters · filed 2024-05-07 | $2.79M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $781.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.14M derived: sum of 3 quarters · filed 2024-03-11 | $2.13M 10-K · filed 2024-03-11 |
| 2022-09-30 | $654.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.02M derived: sum of 2 quarters · filed 2023-11-07 | $2.01M 10-Q · filed 2023-11-07 | $2.47M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $362.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.35M 10-Q · filed 2023-08-08 | $1.81M derived: sum of 3 quarters · filed 2023-08-08 | $324.50M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $990.00K 10-Q · filed 2023-05-09 | $1.45M derived: sum of 2 quarters · filed 2023-05-09 | $324.13M derived: sum of 3 quarters · filed 2023-05-09 | $324.74M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $323.14M derived: sum of 2 quarters · filed 2023-03-09 | $323.75M derived: sum of 3 quarters · filed 2023-03-09 | $433.43M 10-K · filed 2023-03-09 |
| 2021-09-30 | $322.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $323.29M derived: sum of 2 quarters · filed 2022-11-08 | $432.97M 10-Q · filed 2022-11-08 | $433.05M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $110.29M 10-Q · filed 2022-08-09 | $110.37M derived: sum of 3 quarters · filed 2022-08-09 | $110.48M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $109.68M 10-Q · filed 2022-05-09 | $109.76M derived: sum of 2 quarters · filed 2022-05-09 | $109.87M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $194.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.74M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.65M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $1.54M 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $172.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |